Oprozomib

Hematologic Malignancies

Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
Currently enrolling
Study Design: Interventional, non-randomized, open-label
Patients: Patients with multiple myeloma or Waldenstrom Macroglobulinemia with symptomatic relapse
Purpose: To determine the maximum tolerated dose (MTD), activity, and safety of oprozomib in multiple myeloma and Waldenstrom Macroglobulinemia
Locations: Multiple centers throughout the U.S.

Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Currently enrolling
Study Design: Interventional, non-randomized, open-label
Patients: Patients with relapsed and/or refractory multiple myeloma
Purpose: To determine the maximum tolerated dose, activity, and safety and tolerability of oprozomib in combination with dexamethasone
Locations: U.S.